Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

No phase data available

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%

Trials by Status

terminated133%
active_not_recruiting133%
completed133%

Recent Activity

1 active trials
Showing 3 of 3
terminated

Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria

NCT03869593
active_not_recruiting

Prevalence of Epstein-Barr Virus Infection

NCT06444152
completed

Biomarkers for Human Heart Failure

NCT03905252

Clinical Trials (3)

Showing 3 of 3 trials
NCT03869593

Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria

Terminated
NCT06444152

Prevalence of Epstein-Barr Virus Infection

Active Not Recruiting
NCT03905252

Biomarkers for Human Heart Failure

Completed

All 3 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
3